|Circulating DNA as Potential Biomarker for Cancer Individualized Therapy
|Yu Shaorong1, Liu Baorui2, Lu Jianwei1, Feng Jifeng1
|1. Research Center for Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, 210009, China 2. Comprehensive Cancer Center, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Jiangsu Key Laboratory for Molecular Medicine & Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, China
| 1 Sorenson GD, Pribish DM, Valone FH, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidem Biomar 1994; 3: 67-71.
2 Vasioukhin V, Anker P, Maurice P, et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Brit J Haematol 1994; 86: 774-9.
3 Costa DB, Kobayashi S, Tenen DG, et al. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFRmutant non-small cell lung cancers. Lung Cancer 2007; 58: 95-103.
4 Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/ BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15: 4554-60.
5 órtola S, Steinert R, Hantschick M, et al. Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer. J Clin Oncol 2001; 19: 2837-43.
6 Kalikaki A, Koutsopoulos A, Trypaki M, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Brit J Cancer 2008; 99: 923-9.
7 Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790.
8 Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37.
9 Kamat AA, Baldwin M, Urbauer D, et al. Plasma cellfree DNA in ovarian cancer: an independent prognostic biomarker. Cancer 2010; 116: 1918-25.
10 Kumar S, Guleria R, Singh V, et al. Efficacy of circulating plasma DNA as a diagnostic tool for advanced non-small cell lung cancer and its predictive utility for survival and response to chemotherapy. Lung Cancer 2010; 70: 211-7.
11 Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009; 11: 182.
12 Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012; 7: 115-21.
13 Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cell free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012; 18: 1177-85.
14 Yung TK, Chan KC, Mok TS, et al. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009; 15: 2076-84.
15 Lui Y, Chik KW, Chiu RWK, et al. Predominant hematopoietic origin of cell-free DNA in plasma and serum after sex-mismatched bone marrow transplantation. Clin Chem 2002; 48: 421-7.
16 Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in serum of cancer-patients and effect of therapy. Cancer Res 1977; 37: 646-50.
17 Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-65.
18 Choi JJ, Reich CF, Pisetsky DS. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005; 115: 55-62.
19 Jiang N, Reich CF, Pisetsky DS. Role of macrophages in the generation of circulating blood nucleosomes from dead and dying cells. Blood 2003; 102: 2243-50.
20 Stroun M, Anker P. Circulating DNA in higher organisms cancer detection brings back to life an ignored phenomenon. Cell Mol Biol 2005; 51: 767-74.
21 van der Vaart M, Pretorius PJ. The origin of circulating free DNA. Clin Chem 2007; 53: 2215.
22 Rumore PM, Steinman CR. Endogenous circulating DNA in systemic lupus-erythematosus-occurrence as multimeric complexes bound to histone. J Clin Invest 1990; 86: 69-74.
23 Luger K. Structure and dynamic behavior of nucleosomes. Curr Opin Genet Dev 2003; 13: 127-35.
24 Lo YMD, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64: 218-24.
25 Li Y, Zimmermann B, Rusterholz C, et al. Size separation of circulatory DNA in maternal plasma permits ready detection of fetal DNA polymorphisms. Clin Chem 2004; 50: 1002-11.
26 Horlitz M, Lucas A, Sprenger-Haussels M. Optimized quantification of fragmented, free circulating DNA in human blood plasma using a calibrated duplex real-time PCR. Plos One 2009; 4: e7207.
27 Koide K, Sekizawa A, Iwasaki M, et al. Fragmentation of cell-free fetal DNA in plasma and urine of pregnant women. Prenatal Diag 2005; 25: 604-7.
28 Li Y, Di Naro E, Vitucci A, et al. Detection of paternally inherited fetal point mutations for beta-thalassemia using size-fractionated cell-free DNA in maternal plasma. Jama-J Am Med Assoc 2005; 293: 843-9.
29 Umetani N, Kim J, Hiramatsu S, et al. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: Direct quantitative PCR for ALU repeats. Clin Chem 52: 1062-9.
30 Hanley R, Rieger-Christ KM, Canes D, et al. DNA integrity assay: A plasma-based screening tool for the detection of prostate cancer. Clin Cancer Res 2006; 12: 4569-74.
31 Wang BG, Huang HY, Chen YC, et al. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-8.
32 Umetani N, Giuliano AE, Hiramatsu SH, et al. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24: 4270-6.
33 Chan KCA, Leung SF, Yeung SW, et al. Persistent aberrations in circulating DNA integrity after radiotherapy are associated with poor prognosis in nasopharyngeal carcinoma patients. Clin Cancer Res 2008; 14: 4141-5.
34 Jiang WW, Zahurak M, Goldenberg D, et al. Increased plasma DNA integrity index in head and neck cancer patients. Int J Cancer 2006; 119: 2673-6.
35 Ellinger J, Wittkarnp V, Albers P, et al. Cell-free circulating DNA: Diagnostic value in patients with testicular germ cell cancer. J Urology 2009; 181: 363-71.
36 Giacona MB, Ruben GC, Iczkowski KA, et al. Cellfree DNA in human blood plasma: Length measurements in patients with pancreatic cancer and healthy controls. Pancreas 1998; 17: 89-97.
37 Diehl F, Li M, Dressman D, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. P Natl Acad Sci USA 2005; 102: 16368-73.
38 Bastian PJ, Palapattu GS, Yegnasubramanian S, et al. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectorny. Clin Cancer Res 2007; 13: 5361-7.
39 Gordian E, Ramachandran K, Reis IM, et al. Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease. Cancer Epidem Biomar 2010; 19: 1984-91.
40 Altimari A, Grigioni AD, Benedettini E, et al. Diagnostic role of circulating free plasma DNA detection in patients with localized prostate cancer. Am J Clin Pathol 2008; 129: 756-62.
41 Paci M, Maramotti S, Bellesia E, et al. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. Lung Cancer 2009; 64: 92-7.
42 Yoon KA, Park S, Lee SH, et al. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009; 11: 182-5.
43 Catarino R, Ferreira MM, Rodrigues H, et al. Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. DNA Cell Biol 2008; 27: 415-21.
44 Ryan BM, Lefort F, McManus R, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52: 101-8.
45 Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. New Engl J Med 2009; 361: 958-8.
46 Bai H, Mao L, Wang HS, et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages Ⅲ B to Ⅳ nonsmall-cell lung cancer. J Clin Oncol 2009; 27: 2653-9.
47 Wang S, An T, Wang J, et al. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16: 1324-30.
48 Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010; 38: 6159-75.
49 Lecomte T, Berger A, Zinzindohoue F, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002; 100: 542-8.
50 Luo JD, Chan EC, Shih CL,et al. Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 2006; 34: e12.
51 Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-smallcell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-72.
52 Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med 2008; 359: 1757-65.
53 Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
54 Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
55 Loupakis F, Pollina L, Stasi I, et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
56 Massarelli E, Varella-Garcia M, Tang XM, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 2007; 13: 2890-6.
57 Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: An important role for mutations in minor clones. Neoplasia 2009; 11: 1084-109.
58 Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
59 Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 2004; 350: 2129-39.
60 Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. P Natl Acad Sci USA 2004; 101: 13306-11.
61 Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005; 353: 123-32.
62 Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-46.
63 Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010; 16: 790-9.
64 Monaco SE, Nikiforova MN, Cieply K, et al. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010; 41: 94-102.
65 Bouchahda M, Karaboue A, Saffroy R, et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemoth Pharm 2010; 66: 605-9.
66 Kimura H, Suminoe M, Kasahara K, et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Brit J Cancer 2007; 97: 778-84.
67 Board RE, Ellison G, Orr MCM, et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase Ⅱ study. Brit J Cancer 2009; 101: 1724-30.
68 Chuang TCY, Chuang AYC, Poeta L, et al. Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas. Head Neck-J Sci Spec 2010; 32: 229-34.
69 D?britz J, H?nfler J, Preston R, et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Brit J Cancer 2005; 92: 405-41.
70 Jiang B, Liu F, Yang L, et al. Serum detection of epidermal growth factor receptor gene mutations using mutantenriched sequencing in Chinese patients with advanced nonsmall cell lung cancer. J Int Med Res 2011; 39: 1392-1401.
71 Yu S, Wu J, Xu S, et al. Modified PNA-PCR method: A convenient and accurate method to screen plasma KRAS mutations of cancer patients. Cancer Biol Ther 2012; 13: 314-20.
72 Mack PC, Holland WS, Burich RA, et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer. J Thorac Oncol 2009; 4: 1466.
73 Gilje B, Heikkila R, Oltedal S, et al. High-fidelity DNA polymerase enhances the sensitivity of a peptide nucleic acid clamp PCR assay for K-ras mutations. J Mol Diagn 2008; 10: 325-31.
74 Rago C, Huso DL, Diehl F, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res 2007; 67: 9364-70.
75 Thierry AR, Mouliere F, Gongora C, et al. Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts. Nucleic Acids Res 2010; 38: 6159-75.
76 Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008; 14: 985-90.
||TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91.
||Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62.
||QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66.
||MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70.
||LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85.
||WANG Peng. Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside[J]. Journal of International Translational Medicine, 2017, 5(2): 92-97.